cox proportional hazards models
young woman

case-control study
EH

Clinical
cardiovascular system
HF
complications
Cell ; Anand
doxorubicin
doctors


molecular mechanism
dXA
devices ; heart failure
FM
Liver disease
adverse events
HF ; pNA
exercise ; cardiovascular health
Renal artery stenosis
retrospective cohort study
heart transplant recipients
inhospital mortality
ec
tertiary referral centre

DESIGN
heart failure ; Latin America
Retrospective cohort

HF
90-day mortality



doctors

trials
Heart rate
nutrition ; heart failure
Northwest United States
heart failure

Cross-sectional
INTERvenTIONS
unilateral
Heart failure


clin
trans
Sci
Jehovah's Witness


dodson et al

CHF treatments

intermediate frailty
Dynamic ; competitive collateral
autonomic balance
LV fibrosis
HFpEF

functional capacity
Heart failure ; cognitive impairment
cardiology
median followup
HF

inpatient medical conditions
frailty ; HF
CO ; mixed linear models
cardiac transplantation
cognitive function
Heart rate variability ; risk stratification ; cardiac patients
taxonomy
descriptive research
Sham-operated animals


policy recommendations

prognostic meaning
Heart failure ; UK
CHF
air pollution ; heart failure
Patients
cardiovascular disease
HF ; MI
extracorporeal support
Heart failure
hemostasis
DESIGN
ischemic conditioning ; patients ; heart failure
Heart failure ; bisphosphonates
right heart failure ; pulmonary hypertension
Caspase-3 gene expression
diuretic use ; heart failure
functional capacity


hypertension
HF guidelines
Heart rate

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure patients
Literature
MR ; MS
HFpEF
bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF patients
Surgical tactics ; circulatory arrest
functional capacity ; quality
systolic dysfunction
Internal reliability

frailty ; heart failure
median age
AT
implanted monitoring devices
treatments
patient safety
Ea ; afterload burden
periprocedural
RAS ; atherosclerosis
heart failure
microRNAs in heart failure ; disease management
cox regression analysis
PSSS
management ; heart failure ; ejection fraction
Cardiology ; bromodomain inhibition halts heart failure
heart failure hospitalization ; cardiovascular death
mitral stenosis reversed ; medical treatment ; heart failure
vasopressin ; congestive heart failure
Trastuzumab-related cardiotoxicity ; breast cancer
Medication regimen ; sST2
physician volume ; hospital volume
sts HM
pde2 ; HF
Nights spent in hospital
Heart failure ; public health
albumin level
aortic pressure curve
physician continuity
arrhythmia-related costs
heart failure ;HF
Cardiac symptoms
spironolactone ; systolic heart failure
eRK1/2 molecular scaffolds ; heart pathology
Functional MS
epidemiology ; chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox proportional hazards models
Tolvaptan ; vasopressin
systematic review ; network meta-analysis

propensity score

black patients

metric choice ; readmission metrics
eu ; CHF
readmission metric
HF
liMITATION ; Residual confounding
quality of life assessment
median follow
heart failure
mortality ; random-effects models
cardiac ; inflammatory biomarkers
decompensated HF
hgb level ; HRQoL
preserved ejection fraction
biomarkers ; chronic heart failure
Seattle Heart Failure Model
cox proportional hazards models
kidney injury
multiorgan failure ; sepsis
psychometric testing ; Self-Care ; Heart Failure Index
randomized trial ; Nordic walking ; severe heart failure
cox proportional hazard analyses
t1-mapping values
Pharmacological treatment ; acute heart failure
MS
Hemodynamic phenotype ; failing Fontan
Coronary angiography
dialysis patients ; device implantation
off-pump sternal sparing approach ; HeartMate II exchange
VO2max

factors predicting survival
HR
ESRD
mAIN oUTCOME
biomarkers

prognostic factors
heart failure
METHODs

abnormal cardiac T2



risk ; associated treatment strategie
Heart failure ; left ventricular ejection fraction
abnormal HR variability ; cardiac death

chronic kidney disease ;CKD
progressive disease ; hypertension ; kidney failure
hospital ; heart failure
skeletal muscle abnormalities ; exercise capacity ; Fontan circulation
Physician volume
systolic HF
oUTCOME ; readmissions
prognosis
medication ; resting hemodynamics
postystolic
lVAD implantation
patient satisfaction ; sustainability
gross income ; expenditure ; health per capita
aac ; cardiac hypertrophy
AHA ; ESC advocate

HF
aan stage heart failure
HF
patients ; heart failure
acute heart failure trial
toxicity ; systemic blood pressure

cPGs
enrollment
therapy
DESIGN

MS
endothelial function
nursing terminologies
HF ; chromatin hyperacetylation
e-septal
effects of care management ; telehealth
preoperative demographics
public reporting ; quality
sinus rhythm
cardiac rehabilitation
spironolactone ; severe heart failure
Myocardial infarction
HF
anemia treatment ; heart disease
race ; exercise training
Rhythm- and rate-control strategies
ingenuity pathway
algorithms ; post-LVAD AI
severe AI
acute heart failure

QRs duration




deficit index
gLS ; CV events
MS

anaerobic threshold ; heart failure
renin-angiotensin-aldosterone system inhibitors ; heart failure
CHF ; unilateral renal DNx
mitral regurgitation ; HF

Heart block ; pulmonary artery snared
resistin ; metabolism ; heart disease
CAD ; systolic HF
diuretic ; HF
cardiovascular events
bioinformatic analysis ; microarray data
af patients ; echocardiographic examina
functional MS
congenital heart lesions

PVF ; PB characteristics
net economic savings

sst2 concentrations ; BB therapy
MS
ICU mortality
Cardiac function
cRT ; dialysis-dependent patients
beta-blockers
CHF patients

HF
ischemic cardiomyopathy ; male sex
unfolded protein response ; cardiac sodium current ; systolic human heart failure
diastolic dysfunction ; peripheral artery disease
Western blot analysis ; immunohistochemistry ; electron microscopy
angiotensin receptor neprilysin inhibitor ; heart failure
idiopathic dilated cardiomyopathy
hypertensive LV dysfunction ; mild MR ; MS
hypoalbuminemia
prognosis ; c d HF
MS
Protective effects ; exercise training ;ET
fFM ; FM
coronary disease ; heart failure
safety end point
dialysis patients
signalling pathways ; maladaptive cardiac remodelling
heart transplant
af ; precipitating factor
hHF ; dPP-4 inhibitors
bundle branch block electrical activation
Southeastern Minnesota residents
frailty ; HF
proteome ; HDL particles ; shotgun LC-MS
multihospital study ; heart failure guidelines
TAC
Cardiac cachexia ;CC

social support ; lager exercise time
heart rate variation
cRF
Mediterranean ; DASh diet scores
diabetes ; EO-cFUs
risk stratification ; death ; hospitalization ; heart failure clinic
Cardiac-resynchronization therapy ; heart failure
hospital ; readmission reduction program ; congestive heart failure
hFrEF ; HFpEF patients
physician continuity ; urgent readmission ; discharge
nitroxyl ; hNO ; acute treatment ; heart failure
lVET ; follow-up measurement
odds ratios
blacks
pharmaceutically assisted
aerobic exercise
quality measures
trastuzumab-related CHF
transplants
Peak VO2
hospitals


HF ; haemodynamic ; neuronal stressors
Heart failure risk ; rheumatoid arthritis
mortality ; HF hospital admissions ; transplant
Coronary artery disease ;CAD ; systolic heart failure ;HF
preoperative hypoalbuminemia
holosystolic murmur
psoriasis ; atherosclerosis ; incident cardiovascular events
CV death ; non-fatal stroke ; hospitalisation for heart failure
Renal artery stenosis ;RAS ; peripheral arterial disease

adjusted means ; subclinical atherosclerosis
Wilcoxon
ESRD ; outpatients ;HF
ventricular assist device ; right ventricular support
eCGs ; electrocardiographers
right ventricular function ; body composition
deficit index ; biological phenotype
intolerance ; chronic heart failure
eligibility ; heart transplantation
ECCT ; advanced heart failure therapy
Atrial fibrillation ;AF
Fat ; cachexia ; ventricle ; heart failure
AVD ; VVD variations ; free wall RS
preoperative clinical characteristics
renal denervation ; autonomic balance ; conscious rabbits ; chronic heart failure
regulatory subunit ;RI
pediatrc heart failure ;HF
heart failure
high-risk patient ; heart failure ; ejection fraction
cPET guiding exercise rehabilitation ; CHF
eplerenone
ECCT ; cardiac transplant recipients
VEGF inhibition counteracted ; b on cardiac function ; remodeling
Heart failure ;HF ; cardiovascular hospitalization
malfunctioning HeartMate II lVADs
extubated
patient
discharge ; follow-up medication
Î²-blocker ;BB
bromodomain proteins
miRNAs
medications ; heart failure
iCD-HF patients
septal defect
MLHF Questionnaire
coronary heart disease ; stroke ; heart failure

bTT ; DT
heart failure
ST2
HF
biomarkers ; HF
hypotension
Fatal ; nonfatal outcomes

commissie ; CAD
renal dysfunction ; post-transplant morbidity
lVAD implantation
Cardiac hypertrophy ; energy metabolism
NP assessment ; ED patients
trastuzumab

Renal DNx ; circulating plasma NE ; CHF-INv rabbits
Heart failure disease management programs
pre-hCT germline DNA
malondialdehyde ; HDL-induced NO production
HF
blood work drawn
anemia ; heart disease

hospital discharge


readmissions ; follow-up
Myxomas ; pulmonary arterial vasculature
Orthotopic heart transplantation ; oHT
Right atrial myxoma ; pulmonary embolism ; right heart failure
Nfat ; mir-25 ; transcription factor Hand2 in heart failure
resistin ; ejection fraction
Framingham Heart Study criteria ; HF
coronary artery disease
diuretics
HF
east ; rhythm control therapy ; cardiovascular complications
Cardiac overexpression ; Mammalian enabled ;Mena ; heart failure
lVAS support
apoptosis ; canine model ; chronic heart failure induced
dysfunction ; pump failure ; driveline injury
cPCs ; functional capacity ;peak VO2)
fes
Nicorandil ; doxorubicin treatment
soluble (s)ST2
EH ; HFpEF
ischemic ; inflammatory abdominal problems
aCP
medLine ; EMBASE ; cINAHL
ED visits ; intubations ; congestive heart failure
acr ; CMS metrics
HF
hHF ; saxagliptin ; sitagliptin
frailty ; risk ; heart failure ; older adults
band of activated Caspase
Heart T2

device implantation
electronic databases ; World health Organization website ; HF
therapy
degs ; osprey


Medicare ; post-acute care transfer policy
QRS

deficit index
Diet score components ; vegetables ; nuts ; whole grain intake
contrasting groups ; interne consistency
iron
RAS- ; Î²-blocker uptitration
Gastrointestinal bleeding ; ventricular assist devices
QT intervals
bottleneck stent model ; chronic myocardial ischemia ; heart failure
remote monitoring ; hospital discharge ; patients with heart failure
ventricular contractile reserve ; pulmonary hypertension
echocardiograms
Soluble ST2 in ambulatory patients ; heart failure
LV filling pressure ; HF
Titin hypophosphorylation ; myocardial DD
atrial fibrillation ; pacemaker
t1 mapping
medical management ; heart failure ; Canadian Cardiovascular Society
psychosocial factors ; exercise training ; heart failure
emergency cardiac catheterization
pump exchanges ; pump malfunctions ; pump thrombosis

HRQoL ; exercise training
noc outcomes
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure

inpatient records ; HF
aRIC HF model
skeletal muscle mass correlated ; poorer VO2 max
ees ; ventricular-arterial coupling
pneumonia ; surgical conditions
autonomic nervous system ; QTV
diastolic failure ; cardiomyopathic restriction
therapy
iCD-HF patients
human myocardial tissue
body mass index ; cRF ; treadmill exercise testing
AF-free probability
paediatric cardiac transplants
ethics Rounds
high-risk patients
diet adherence


model
renal DNx ; cardiac autonomic balance ; CHF
ivabradine unloads ; left ventricle ; heart failure patients
anemia ; heart disease
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
end-stage renal disease ; systolic heart failure
Heart Failure ; Pathophysiology ; Diagnosis ; Medical Treatment Guidelines
RVPO ; BiVP ; CO ; RS synchrony ; CS
parasympathetic neurotransmission ; acetylcholinesterase inhibition
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
Neurohormonal abnormalities ; congestive heart failure ;CHF
chronic heart failure ; lipoprotein
cardiovascular death ; HF hospitalization ; exercise training
acute autonomic nervous system modulation ; QTV
resistin ; anthracycline-induced cardiotoxicity
Myocardial pde2 expression ; activity ; advanced human HF
clinical outcomes
Heart rate ; aortic blood flow
BAT ; sympathetic outflow ; parasympathetic
congestive heart failure ;CHF
chromatin subproteome ; mouse heart
pulmonary artery
resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxicity
cPCs ; outcomes
mediterranean ; DASh diet scores ; mortality ; heart failure
LVEF ; long-term mortality
dobutamine ; furosemide dose ; oxygen flow
miRNAs ; therapeutic targets
Jehovah's Witness ; sickle cell disease
mRI scanner
health Buddy Program ; ED
clinical ; therapeutic
l-type ca2+ currents ; Rad variant ; congestive heart failure
physician continuity
cardiac stress ; Î²-AR drive
PSSS ; social support
contemporary therapeutic options
frailty ; elderly
muscle-wasting syndrome ; acquired heart failure
Health Buddy Program ; content-driven telehealth system
bisoprolol ; reducing mortality
ED visits ; CHF intubation rates
Medicare fee-for-service beneficiaries
student t test ; cis
myocardial diastolic dysfunction ;DD
systolic ; diastolic mitral leaflet motions
Stress Doppler echocardiography ; pulmonary hypertension patients
circulating progenitor cells ; outcome ; heart failure patients
LV strain ; strain rate
septal wall CS ; free wall CS ; VVD
etiologic causes ; acute RV failure ; left ventricular dysfunction
biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
circulatory assist device
morbidity ; mortality
cPCs ; functional capacity ; heart failure
ctnt ; NT-probNP ; HF risk prediction
inhibition ; protein kinase ; soluble guanylate cyclase
HR reduction ; beta blockers ; exercise capacity
sympathetic activity ; i-MIBG myocardial washout
proof-principle cohort
cardiopulmonary exercise variables
inhospital mortality
HF
heart failure ;HF
ventricle ;RV ; cardiac function
Mortality
RV dysfunction
transcatheter
beta blockers
PD ; refractory ; end-stage congestive heart failure
HF ; mVA
pressure ulcers ; surgical patients
median baseline ST2 level
verficacy outcome
therapeutic functions
Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
black race ; mortality
hierarchical regression models
Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
sociale support ; barriers
NYHA functional assessment
chelation regimens

test-retest reliability
complication

Thirty-day mortality
futility
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
aortic valve insufficiency ; ventricular assist device implantation
ventricular ejection ; acute heart failure complicating precapillary pulmonary hypertension
pacing-induced dilated cardiomyopathy
right atrium mass ; prolapse ; tricuspid valve
California office of Statewide healthplanning and Development Patient Discharge Data
cardiac catheterization ; thrombotic obstruction ; right coronary artery
echocardiographic ; invasive hemodynamic
HFPEF ; dietary sodium restriction ; ventricular ; vascular stiffness
functional capacity
chronic heart failure ;CHF ; sympathetic tone
CHF atrial explants ; c-Kit+ cells
magnetically Levitated left Ventricular Assist System ; Treating Advanced HF
Fontan failure ; systolic ventricular function
Heart failure ; mortality
HF
extracorporeal membrane oxygenation ; bridge to recovery in infarction-related refractory right heart failure
protein levels ; Western blot ; DNA fragmentation ; TUNEL
EH ; cardiac filling pressures
implantable cardioverter-defibrillator deactivation
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
trastuzumab ; cardiac comorbidities
mechanistic insight ; prolonged electromechanical delay ; dyssynchronous heart failure
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
economic impact ; af ; heart failure

bundle-branch block ;LBBB
BETs ; mouse TAC model
patients ; preserved systolic function
HDL-induced NO production ; flow-mediated dilatation
cPG recommendations
cox regression ; cardiovascular events ; psoriasis
heart failure ; altered protein kinase
NT-probNP
dopamine
resource use ; quality of life
HF
patients ; aHF
nitrite
neurological ; cardiovascular
MADit-cRT
consultations
transfusion thresholds
Czech Republic
cardiac nurses
study closure
concordance c statistics
absolute risk ; heart failure
kosten-effective ; participatory
serum albumin levels ; survival ; left ventricular assist device implantation
Western blots ; monoclonal antibodies ; Ser83 phosphorylation
treatment ; HRQoL
interleukin receptor family member ST2 ; beta-blocker therapy ; chronic heart failure
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
echocardiography evaluations
exercise intolerance ; heart failure
functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
New York Heart Association classification ; quality-of-life scores
pathophysiology ; HF
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure patients
Paco2 cerebral blood flow ; perfusion ; carotid bodies
cox models
ED physicians
TM interventions
psoriasis patients ; smoked ; diastolic blood pressure
ECmo group ; VAD ; ECmo+VAD groups
inotropic effect ; beta blockers
anticoagulation ; therapy ; underlying heart disease
mortality ; morbidity
energy metabolism ; heart failure
NT-probNP ; HF patients
ivabradine ; TAC
PAD ; ankle-brachial index
functional MS
mechanical cardiac support ; renal
renal dysfunction ; mechanical cardiac support
device
ventricular dilatation
aanemia in patients with heart disease
CF lVAD patients
rhythm-control ; rate-control
systolic heart failure
HF epidemiology ; relevant health service provision
Functional MS
hemoglobin levels
ventricular assist devices
Heart failure ;HF
heart failure ;HF
serum factors
cfa
PB ; patients ; HF
nontreatment
computing readmissions ; pay-for-performance
iCD patients

wind cohort
pro-adrenomedullin ;MR-proADm
Cardiorespiratory fitness ; body mass index ; heart failure mortality
bNP ; NT-probNP
diet ; exercise ; attention control
adenyl cyclase ; differential g-protein coupling
heart failure ;HF ; ventricular ejection fraction ;HFpEF
circulating fragments ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure patients
ejection fraction ;EF ; infarct size ; collateral growth ; myocardial perfusion
Heart failure ;HF ; sympathetic activity ; parasympathetic control
Atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control strategies
cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
ATP demand ; XO-mediated ROS ; mitochondrial respiration
Predictors ; mortality ; implantable cardiac defibrillator
end-stage heart failure ; ventricular assist device
systolic HF ; unclear etiology ; coronary angiography
HF ; cardiac murmurs
Exercise intolerance ; chronic HFPEF
isoproterenol ; cXL-1020
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
autonomic modulation ; repolarization instability ; heart failure prone to ventricular tachycardia
b treatment ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
biventricular dysfunction ; isolated HeartMate II
HF ; spontaneous VT
social mandate
signaling pathways ; pressure-overload-induced heart failure
TUG test ; advanced COPD ; CHF ; cRF
hemodynamically unstable ; cPR
ecmo group ; eGFR
gastrointestinal
aCS procedures ; MT ; VAD
HR ; tNF antagonists
psoriasis ; cardiovascular outcomes
SCHFI v.6.2
energy substrate metabolism
CVD ; psoriasis
diabetes mellitus ; cardiovascular disease
CAD
hospital ; cardiac specialty hospital
haemodynamic ; pulmonary
medical records
diagnostic performance ; prediction rule
HF-related cachexia ; RV function
cognitive impairment ; mortality
rehospitalization

acute HF
trastuzumab-related CHF
long-term survival
hospitals
biomarker-guided clinical trials
cardiac death
mechanical cardiac support ; renal function
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
heart transplantations ;LV assist device implantations
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
mouse HF model ; compensated LV hypertrophy ; HF
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
natriuretic peptide levels ; biomarkers
sympathetic ; parasympathetic activity
bNP levels ; PAD ; bNP measurements ; HF
Spironolactone ; hyperkalemia ; acute kidney injury
chronic myocardial ischemia ; heart failure
EH ; systolic blood pressure ; renal impairment ; hypertension
HFpEF ; adverse outcomes
race ; outcomes
parasympathetic function ; therapeutic
Heart failure ;HF
jugular venous pressure ; peripheral oedema
aggressive medical treatment ; HF symptom ; MS
Baseline Hgb ; exercise training ; KCCQ
Surgical revascularization
techniek ; redo sternotomy ; cardiopulmonary
clinical prediction rule
Morpholino-based knockdown ; nucleolin ; protein expression
MS ; HF
HF
Cytoscape ; functional enrichment analysis
blacks ; hypertension ; diabetes ; ischemic etiology
NT-probNP testing ; acute heart failure
health insurance ; health system data partners
lVAD ; biventricular support
Fontan circulation ; cardiac index
Fontan circulation ; skeletal muscle mass
hereditary ; congenital abnormalities ; heart ; nontraumatic death
mineralocorticoid receptor antagonists
lVAD support ; postoperative survival
isolated HeartMate II lVAD
practice settings
bisphosphonate users ; heart failure
right heart circulation
Raf-MEK1/2-ERk1/2 signalling pathway
MI ; HF
HF-induced remodeling ; EMD prolongation
long-term costs ; survival
sustainability ; hospital-based programmes
maladaptive molecular processes
patient safety initiatives
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac volume overload
spironolactone ; systolic heart failure
nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis
myocardial ischemic events ; cardiac resynchronization
Î²-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
HF ; preserved ejection fraction ;HFpEF ; hypertension
heart failure ;HF ; Heart Failure Adherence ; retention trial ;HART
HFpEF
Myocardial infarction
NYHA functional class ; quality-of-life score
aortic valve surgery ; post-LVAD
immunodetection ; NT-probNP
unloading ; heart ; isolated HR reduction
Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
oxidative stress ; small GTPase Rac1 activity
inpatients with heart failure
cardiovascular death ; urgent cardiac transplant
Resistin ; circulating mediator ; insulin resistance ; monocytes ; inflammatory stimuli
Heart failure ;HF ; Latin America ;LA
Heart failure ; atheromatous coronary disease
palliative care ; patients
HF hospitalization ; cRT
medicare fee-for-service
HFpEF




psoriasis ; systemic/UV treatment
non-ischemic ; ischemic heart failure
stress conditions ; maladaptive remodelling
heart failure ; Emergency Department ;ED ; ED volume
Intravenous iron ; iron deficiency
RV dysfunction ; weight loss ; abnormal body composition
PD ; therapy ; severe end-stage HF
diastolic dysfunction ; HFPEF
chrmatin-associated proteins ; chromatin structure ; DNA
NT-probNP ; HF patient plasma ; immunoprecipitation
ventricle overload ; stroke volume ; left ventricular ejection time
Î²-Adrenergic receptor blockade
congestive heart failure
mitochondrial structure ; sarcomeric microstructure
CHF patients ; emergency department ;ED
LCx ; LAD models ; two-vessel disease model
pPR ; acr ; CMS metrics
gut ; inflammation ; dietary interventions
practice-level differences
robot-assisted gait therapy ; LokomatÂ® system
aIM
pulmonary hypertension ;PH ; heart failure
lVET
exertion ; therapeutic treatments
cardio failure ; diabetes ; heart failure
ET ; HDL function ; CHF-NYHA-IIIb
antiarrhythmic drugs ; rhythm control therapy
therapeutic interruption ; activated neurohormonal systems
spironolactone
microRNAs ;miRNAs ; heart failure
Beta-blocker dose
QT variability ;QTV ; repolarization lability ; QTV
conscious ; chronically instrumented New Zealand White rabbits ; renal DNx ; pacing-induced CHF
consenting ambulatory HF patients
paraDIGm-HF ; paradigm shift ; chronic heart failure Chronic heart failure
early physician follow-up after discharge
dialysis patients
zSF1 rats ; heart failure ; preserved ejection fraction
transoesophageal echocardiography ; patent ; thrombosis
mutant mice overexpressing Hand2 ; healthy heart muscle cells ; pathological hypertrophy
heart ; adipose tissue ; cachectic heart failure patients ; body composition
arterial tonometry study ; lVET carries prognostic value ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation choices ; cardiovascular disease ; thalassaemia
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
POc technology
interne ; external validity ; replicating resource use
cardiovascular disease
Rhythm control therapy
proteins
readmissions
AMI mortality rates
psoriasis ; cardiovascular disease
e-septal
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure
Hemoglobin ; exercise training ; health status ; chronic heart failure
RAS-blocker uptitration ; clinical outcome
Myocardial collagen ; collagen cross-linking ; titin isoforms
Cardiac magnetic resonance postcontrast
diastolic dysfunction ; filling pressures ; doppler echocardiography
dRS deciles
inappropriate therapy
diagnosis ; early medical management
cardiac remodeling ; heart failure
frailty ; risk for heart failure ;HF
heart failure ; bisphosphonates
quality of care programme
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
index admission
Plasma samples ; HF patients
alendronate
transduction pathways ; signalling proteins

GDMT ; BAT
cncka sNP
clinical diastolic dysfunction
aCS problems ; oHT bridged to transplant ; MT
RAS- ; Î²-blocker dose
regulation of feeding ; nutritional strategies
PRInciPAL FINDINGs ; hospital rates ; HF patients
Bax ; bcl-2 proteins
HF ; rheumatoid arthritis ;RA
Î²-Blocker-induced enhancement ; cardiac angiogenesis
symptomatic adult Fontan ;SAF
natriuretic peptides
AlphaLISaÂ® immunoassays ; NT-probNP
doxorubicin ; anti-neoplastic agent
heart failure ; preserved left ventricular ;LV
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
c-statistics ; biological phenotype
HF ; HFrEF
LV diastolic dysfunction
ambulatory iCD patients ; predictor ; mortality
fes ; preserved ejection fraction ;HFpEF
Myxomas ; cardiac benign tumors
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
Gastrointestinal bleeding ; ventricular assist devices
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
Renal denervation ;DNx ; CHF patients
physician follow-up ; physician continuity
Crude rates ; severe hyperkalemia ; acute kidney injury ; spironolactone
Heart failure ; preserved ejection fraction ; hFPEF ; cardiovascular reserve
heart failure ; elevated left atrial pressure
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
refractory congestive heart failure ; peritoneal dialysis
MT ; VAD groups ; aCS
bNP ; NT-probNP ; coronary artery disease ;CAD
proces redesign contextual framework
aerobic capacity ; left-hand grip strength
ecCT
NT-probNP
control group ; exercise group
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation
predictors ; heart failure-related hospitalization ; death ; left ventricular ejection
Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
heart failure ; preserved ejection fraction ; hFPEF
lean zSF1 group ; hypertensive ; obese ZSF1 groups
tissue doppler imaging ; left ventricular filling pressure ; systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF
activating myocardial PDE2 ; antiadrenergic therapeutic strategy ; HF
ICU admission ; precapillary PH ; heart failure
Myocardial loss ; IRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure mice model ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy
transfusions ; heart disease
PVF ; PB cycle
sST2 ; low-dose BB
eCG parameters ; cRT
remote monitoring ;RM
RV dysfunction ; cardiac cachexia
chronic heart failure ; Hungary
HF hospitalization
exercise ; diet
spironolactone
carotid intima-media ; psoriasis
coronary occlusion ; collateral growth
Mechanical dyssynchrony ; QRS complex
pharmacologic treatment
i ; heart failure ;HF ; cRT-D
breast cancer patients ; trastuzumb-related CHF
pde2 ; failing hearts ; desensitizes against acute Î²-AR stimulation
anemic ; iron-deficient adult patients
Point-of-care systems ; NP levels ; ED ; community outpatient settings
EO-cFUs ; reducd mortality
trastuzumab ; CHF
eGFR ; diuretics ; uncontrolled hypertension ; ESRD
heart failure ; hospitalisation
acute heart failure ; aHF
psoriasis patients ; psoriasis
HF remodeling aspects ; extending EMD ; dyssynchronous failing heart
aggressive dose uptitration
anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HF ; hypertension ; vasodilators ; diuretics
aldosterone antagonist
angiogenesis ; post-myocardial infarction heart
heart failure ; ejection fraction ; myocardial infarction
lVAS
HDL function ; CHF ; ET
HF risk factors ; fit men
physician adherence to HF cPGs
HFPEF

black race ; HF hospitalization ; cardiovascular mortality
coronary artery disease ; systolic heart failure
arterial compliance ;TAC ; end-systolic elastance ; ees
Renal dysfunction ; cardiovascular events
isoprenaline infusion ; SDQT
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting
Biventricular support ; HeartMate II lVAD ; CentriMag rVAD
Pyridostigmine ; vascular endothelial growth factor protein ; left ventricle
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic
dopamine ; nesiritide
nonprescribing ; chart review
biomedical reasons ; nonprescribing
ERC ; pure epicatechin
Care management ; content-driven telehealth technology
Ea ; TAC ; HR ; ees
HF
CHF ; international Classification of Diseases
MEDline ; EMBASE ; cochrane databases ; clinical trial registries ; reference lists ; technical advisors
egFR ; VAD group ; ECMO
idiopathic dilated cardiomyopathy cohort
cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling events
Robot-assisted gait therapy ; LokomatÂ® system
cRF ; HF mortality risk ; HF risk factors
RV dysfunction ; lower body mass index ; fat mass index
myocardium displays altered expression ; pKA subunits ; downstream signaling
elastic N2 bus segment ; PEvk segment
quantitative proteomics ; chromatin-associated proteins ; detergent
cXL-1020 converts ; hno ; inactive cXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart
pharmacologic management ; acute HF
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats
HeartMate ; left ventricular assist system ; lVAS
onderzoek ; heart failure patients ; implantable cardioverter-defibrillator
Self-Care of Heart Failure Index ;SCHFI v.6.2
inappropriate therapy ; atrial fibrillation
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus Report Heart failure
segment-elevation MIs ; Killip class
management ; end stage heart failure Heart failure
HeartMate II insertion ; biventricular support
functional MS ; valve plasty ; degenerative MR
tNF antagonists ; HF hospital admissions ; nbDMARDs
physician adherence
magnet(Â®
risk-adjusted mortality
exercise ; diet
gLS ;HR ; ci
ejection fraction
epidemiology ; myocardial infarction ;MI ; heart failure ;HF
Heart rate reduction ; exercise performance ; heart failure ; ejection fraction
isoelectric focusing ; RIÎ±
NT-probNP ; MR-proANp ; MR-proADm
mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
natriuretic peptide ; creatinine
RAS ; hypertension ; nephropathy ; congestive heart failure
SDQT to SD ; RR intervals ;SDRR ; index ; QTV ; heart rate variability
cardiac magnetic resonance imaging ; T1 mapping ; invasive hemodynamic assessment
HF ; biosynthetic enzymes ; lyso-PAF-AT
cardiac events
sST2/low-dose BB ; sST2/high-dose BB
HF complicating AMI
LV ejection fraction
zebrafish ; nucleolin ; genomic reprogramming events
Physician volume ; lower mortality ; HF
CHF visit rates
Logistic regression models
eGFR ; VAD group ; ECMO+VAD group
eseptal ; e/emean
gastrointestinal bleeding
readmission rate ; patients ; heart failure
diuretics
congestive heart failure
IVc occlusion ; CO correlated ; twist ; apical rotation ; RS synchrony
emergency department ; acute heart failure clinical trials
heart failure ;HF ; risk stratification models
carvedilol ; metoprolol ; heart failure patients
BET bromodomain-containing protein 4 ;BRd4)
in-trial resource utilization ; unit costs
mitral valve plasty ; degenerative mitral regurgitation
intravenous iron
erythropoiesis-stimulating agents ; anemia ; heart disease
public health ; air pollution ; industrial areas
molecular biomarkers ; HF
cardiopulmonary ; life score ; muscular strength ; peak quadriceps force
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
Morbidity ; mortality ; HFpEF
conscious HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control
idiopathic dilated cardiomyopathy ; tuscany
eCG ; congenital accessory pathways ; ion channelopathies
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
af ablation
heterogenous improvement ; ejection fraction
echocardiographic score ; cRT
economische models ; lVAD
METHODs

t1-mapping sequence ; tidal respiration
Medicare inpatient data ; HF admissions to acute hospitals
HF ; preserved ejection fraction ; pEF
mouse HF model ; HHD ; salt loading ; uninephrectomy ; ANG II infusion
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
dopamine ; nesiritide ; acute heart failure ; renal dysfunction
catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
RV failure ; management strategies
Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; c-Kit+ cells
Mortality ; inpatient admissions ; hospital days
HF ; MI ; ejection fraction
METHODOLOGY
HeartMate II lVAD ; CentriMag rVAD
HFpEF ; kccq
serum creatinine level ; serum potassium level
PD initiation ; diuretic response ; peripheral edema
echocardiographic predictors ; response after cardiac resynchronization therapy ; cRT
circulating NT-probNP concentration ; antibodies targeting nonglycosylated
University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
anemia ; chronic heart failure ;HF
Hum-Retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes
chromatin subproteomes ; heart failure
nbDMARD ; tNF antagonist
HFrEF ; exercise performance ; resting HR
XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic ACF
heart failure nurses ; cardiology services
heart failure ;HF ; maximal cardiopulmonary exercise test ; anaerobic threshold
renal dysfunction ; stroke ; myocardial infarction ; heart failure
cox hazard models ; time to ESRD ; to death ; ESRD ; death
randomised-controlled trials ;RCts
pyridostigmine administration ; methylatropine ; propranolol
paf ; metabolic enzymes ; heart failure ; healthy volunteers
trastuzumab ; adjuvant setting ; cardiotoxicity ; congestive heart failure
carvedilol ; thromboembolic events ; heart failure ; Î²2-receptor haplotype status
Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses
echocardiographic ; N-terminal pro-brain natriuretic peptide ; inflammatory markers
myosin binding protein-C phosphorylation ; Ser23/24 troponin I phosphorylation
uPR effectors ; protein kinase r-like ER kinase ;perk ; calreticulin ; CHOp
HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility

deactivation
nutritional abnormalities ; CHF
kosten ; high-volume physicians
doxorubicin ; doxorubicin ; ip ; serum resistin levels
pigs ; inferior vena cava ;IVc
direct observation ; mVA
post-hCT CHF
recreational athletes ; sudden cardiac deaths ; males
oxygen consumption ; oxygen pulse
dialysis-dependent patients ; HF ; cRT implantation
RV
CHF-developed infarcted animals ; left ventricle end-diastolic pressure
womens health Initiative ; HF hospitalization
economic climate ; NHs ; behavioural-change interventions ; chronic disease ; exercise programmes
aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
CV deaths ; non-fatal stroke ; hospitalisations for heart failure
biomarkers ; molecular dysfunction
Ambient air pollution ; cardiovascular health
VAD group ; ECMO+VAD group
ischemic ; ischemic heart failure ; biomarkers
gLS ; index beat method ; CV events ; cox proportional hazards analyse
reclassification ; risk ; c statistic ; net reclassification ; integrated discrimination improvement
east ; rhythm control therapy ; AF
mena ; cardiac injury ; mena ; HF
scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
lipolysis ; energie expenditure ; natriuretic peptides ;NPs
cox proportional hazards models ; health behaviors ; health status
tAPse ; PASp ; tAPse
Right ventricular ;RV ; left ventricular assist device ; lVAD
albumin levels ; nutrition ; inflammation ; hepatic function
kccq overall Summary scores ; kaplan-Meier curves ; death
Olmsted County ; Minnesota ; MI diagnosed ; HF
HF
sensitivity ; CAD
inhibition of vascular endothelial growth factor ;VEGF ; compensatory hypertrophy to cardiac failure
left ventricular ejection fraction ; long-term mortality ; heart failure Survey in ISrael
neurohumoral blockers ; HF hospitalization
odds ratio/hazard ratio ; death ; HF ; AMI
testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
health Buddy Program ; chronic obstructive pulmonary disease ; congestive heart failure
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
IC ; multicenter Automatic Defibrillator Implantation ; trial-Cardiac resynchronization Therapy
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted
AMI ; heart failure ; kidney infection ; UTI
renal underperfusion ; renin- angiotensin-aldosterone pathway
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
HR dynamics ; HR variability ; risk stratification
cRT-D ; defibrillator-only therapy
diagnostic procedure
HF ; index AMI
apoptosis ; pathogenesis ; heart failure
BETs ; transcriptional pause release ; transcription
lVAD ; transplantation eligibility status
LVEF
uPR ; na+ channel mRNA splice variants ; cardiac na+ current ; HF
diuretic efficacy ; neurohormonal activation ;congestion-like
eCG ; atherosclerotic CAD ; sudden cardiac death
diabetes mellitus ; metabolic risk factors ; comorbidities ; heart failure ; preserved ejection fraction
Cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling
percutaneous coronary revascularization ; hemodynamically stable
inappropriate therapy ; atrial fibrillation ; atrial tachyarrhythmias
speckle tracking echocardiography ;STE ; BiVP ; ventricular pressure overload ;RVPO
dose uptitration ; HR reduction
ANS mice ; LV fractional shortening
programmed cell death
Rad variant ;Q66p ; congestive heart failure
systolic heart failure ; spironolactone
Trastuzumab ; CHF ; nontrastuzumab users ;hazard ratio ;HR
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension
perk inhibition ; full-length sCN5a ; Kv4.3 mRNA levels ; na+ channel mRNA splice variants
bottleneck stent ; myocardial infarction
sex ; EF ; bNP ; HF patients
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
echocardiographic score ; LV reverse remodeling
salt loading ; uninephrectomy ; ANG II infusion mouse model ; cardiac function
Mena expression ; HF ; mena ; cardiac pathophysiology
LVEF ; long-term mortality ; acute decompensated HF
atrial fibrillation ; aanrial fibrillation ; Stroke prevention Trial
voordelen ; controlled randomized trials
NP measurement ; POc measurement ; NPs
RECENT FINDINGs ; intestinal morphology ; permeability ; absorption function
hoog-volume physicians ; readmission rates ; hospital volume groups
etiology ; comorbidities
cardiac hypertrophy ; nucleolin
peak work rate
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
ARNI ; cardiovascular mortality ; hospitalization for heart failure
figuur ; anaerobic metabolism
idiopathic dilated cardiomyopathy
fibrosis ; heart failure myocardial tissue ; left ventricular tissue ; trichrome blue histologic
Kansas City cardiomyopathy Questionnaire ; kccq ; HF ; HFpEF
Blood pressure ; arm cuff ; stroke volume ;SV ; ejection fraction ; end-diastolic volume ; echocardiography
biventricular support ; hybrid system ; HeartMate II lVAD ; CentriMag right ventricular assist device ; rVAD
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure
right ventricular ;RV ; body composition
American College of Cardiology ;American Heart Association guidelines on evaluation ; management ; patients ; RAS
frailty ; heart failure ;HF
functional MS ; degenerative MR
implantable cardioverter-defibrillator deactivation
EO-cFUs ; lower CD34+vegFR2+ cells
functional MS ; valve plasty ; degenerative MR
HF patients
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ;ECMO
sNP rs10927887 ; ka renal chloride channel gene ;CLCNKA
circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular diseases
HF-ACTION cohort ; baseline Hgb ; baseline HRQoL ; kccq
cardiac hypertrophy ; HF ; fibrosis ; inflammation
NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction
contractile function ; LV dilatation ; LV end-diastolic pressure/wall stress
LV remodeling ; diastolic properties ; XO inhibition
simulations ; virtual cohorts

blood pressure control ; goal-directed lipid-lowering therapy ; smoking cessation
SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
bTT ; DT
health per capita ; gross national income per capita
cRT-D recipients
bNP ; inhospital mortality
t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
AF
RAS- ; Î²-blocker uptitrations ; hFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma
HFpEF ; echo-Doppler cardiography
DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis
implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
frail
hFPEF
LBBB ; implantable cardioverter defibrillator-CRT
standard error of measurement ; mDC
embryonic gene programs ; pathological heart disease
acute heart failure ; aHF
RM strategies
skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; cardiac resynchronization therapy ; cRT
pasp
sst2/low-dose BB ; sST2/high-dose BB
mitochondrial complex v activity ; aac
eplerenone ; HF-REF ; hyperkalemia ; wRF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor
Physician volume ; HF
isolated heart rate ;HR ; ivabradine ; systolic heart failure
biomedical treatment ; CHm ; biomedical treatment ; dCM
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;CORAL ; stenting ; RAS
Yorkshire swine ; pacemakers ; ventricularly paced
echocardiographic score ; reverse remodeling ; cRT
Mediterranean ; Dietary Approaches to Stop Hypertension ;DASh ; mortality ; postmenopausal women ; HF
therapeutic left-to-right interatrial shunting ; heart failure
cardiovascularverter defibrillators ;ICds
heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
pulmonary hypertension patients ; ventricular contractile reserve
implantable cardioverter-defibrillator
perk activation destabilized sCN5a ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems
POc systems ; measuring NP levels

quality ; functional capacity
electronic databases ; MEDLINE ; EMBASE ; PsycINFO
echocardiography ; cardiac diameters
LBBB ; QRs ; implantable cardioverter defibrillator-cRT
risk-adjusted mortality ; readmissions ; costs
international Right Heart Foundation Working Group
HF risk factors ; HF epidemiology ; SH ; c'd ; rheumatic fever
cardiac myocyte-specific Mena overexpression ;TTA/tetMena
HFpEF ; diastolic filling time ; controlling heart rate
guideline-recommended medications ; heart failure ; reduced ejection fraction
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction
caloric restriction ;diet ; aerobic exercise training ;exercise ; QOL ; obese older patients
antiplatelet agents ; anticoagulants
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance
r. Cluster analysis
figuur ; fFM
therapeutic strategy ; AF ; severe heart failure
cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction
inpatient assessments ; patients with heart failure ; hospital discharge ; readmissions
interagency Registry for Mechanically Assisted circulatory Support
na+ channels activate unfolded protein response ; uPR ; scn5a electric remodeling ; HF
crude ; ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
myofiber dynamics ; myofiber shortening ; EMD ; dyssynchronous HF
Fontan failure ; hemodynamically ; traditional heart failure ; systemic vascular resistance ; sVR ; preserved cardiac index
allopurinol ; contractile function ; efficiency ; XO-mediated ROS effects ; myofilament Ca(2+) sensitivity
baseline Hgb ; kccq scales ; hgb ; exercise training on HRQoL
ventricular ejection fraction ; left ventricular diastolic end diameter
Î²-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
left ventricular ejection fraction ; heart failure ; HFpEF
eccentric versus concentric left ventricular hypertrophy ; heart failure
isolated heart transplant
median rate ratio ; therapy
et on HDL-mediated protective effects ; molecular pathways ; chronic heart failure
cRF ; HF mortality
AT ; metabolic exercise ; cardiac ; kidney index score
risk ; heart failure ; refill compliance ; etidronate
Medicare hospital claims ; post-acute care transfer policy
physicians ; management ; patients ; advanced heart failure
bNP ; e/e
systolic function ; HFpEF patients
scn5a variants ; AngII ; hypoxia ; exogenous variants ; uPR
NT-probNP assay targeting nonterminal epitopes
g-protein-coupled receptor kinase-2
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
concurrent HF
dopamine ; nesiritide ; decongestion
alendronate- etidronate- ; raloxifene
diagnostic approaches ; clinical trials
implantable cardioverter defibrillator-CRT ; non-LBBB
kccq domains ; HFpEF ; cronbach
anemia ; iron deficiency ; MEDLINE ; cochrane Library
HART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
left ventricular assist devices ; lVADs
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
extracellular matrix ; left ventricular biopsies ; tissueFAXS technology
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis/gluconeogenesis
ST2 ; amino-terminal pro-b-type natriuretic peptide
conscious dogs ; tachypacing-induced HF ; cXL-1020 contractility
chemotherapy ; trastuzumab use ; comorbidities ; CHF
contemporary heart failure ;HF ; therapies
metric ; performance
sST2/high-dose BB
saxagliptin users ; sitagliptin users
t1 changes ; myocardial collagen
Sprague- dawley rats ; sham ; ACF ; allopurinol
cardiac plasma membrane levels ; s1PR1 ; overstimulation ; heart failure
neurohormones ; adipokines ; body composition ; CC ; fat mass
fully magnetically levitated lVAS ; mortality risk
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
biventricular pacing ; biVP ; cardiac output ;co
Myocyte hypertrophy antecedent to heart failure ; global gene expression
rGK protein
creatinine ; BNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
AlphaLISa immunoassays ; antibodies targeting the extreme N ; c termini ; circulating NT-probNP
New York Heart Association ;NYHA ; chronic heart failure ; reduced ejection fraction
Catheter ablation for AF ; compensated HFPEF ; left ventricular ;LV
transplantation to consultation
cRT group ; control group ; hazard ratio
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium
BB therapy ; sST2 measurement ; chronic heart failure
biventricular support
functional efficacy ; pure HNO donor to enhance myocardial function
TUnel assay ; apoptotic cells ; tunel-positive cells
tAPse vs PASp relationship ; length-force relationship ; RV function evaluation ; LV dysfunction
ESRD ; systolic HF ; eGFR
congestive heart failure ; non-urbanized Midwestern state
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure
cox proportional hazards models ; score ; death ; transplantation ; LV assist device implantation ; heart failure hospitalization
race ; exercise training ; chronic heart failure
risk for Hospitalized Heart Failure ; Saxagliptin ; Sitagliptin ; antihyperglycemic Drugs
intraclass correlation coefficient ;ICc ; kappa coefficient ; standard error of measurement ; mDC
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation
biological phenotype ; deficit index ; medical records
Cardiology practices participating in the National Cardiovascular Disease Registry practice Innovation ; Clinical Excellence registry
tachycardia ; intravenous atropine ; cardiac vagal tone
CHF ; cardiac explant c-Kit+ progenitors
transitions of care program
myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
sts HH ; TM ; medical support
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure
SDQT ; HFVT ; HNorm group ; Î²-adrenoceptor blockade ; esmolol
heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
STUDY DESIGN
Peripheral artery disease ;PAD ; heart failure ;HF
echocardiographic score ; LV reverse remodeling
Renal dysfunction ; heart failure ;HF ; renal disease ;ESRD
hno donor ; cXL-1020) ; intact hearts ; HF
drug-free
protocol-driven POc testing ; NP ; patient consultation ; ED
shuttle walk test ; body mass ; hand grip strength
physician volume ; mortality
capillary ; coronary perfusion ; ad-Flk rats
race ; chronic heart failure ;HF ; exercise training response
leaflet configurations ; serial evaluation
heart failure ; CHARM programme ;Candesartan in Heart Failure Assessment ; Mortality ; Morbidity
undirectional left-to-right interatrial shunting ; patients with heart failure ; ejection fraction
heart failure ; left ventricular ejection ; spironolactone
Nicorandil ; decrement ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction heart failure patients
myocardial extracellular matrix ; cardiac magnetic resonance T1 mapping ; pathobiology/pathophysiology
bMI ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure
Troponin T ; n-terminal pro-b-type natriuretic peptide ; biomarker approach to predict heart failure risk ; atherosclerosis risk
exercise ; cell senescence ; active individuals ; cancer ; prostate ; colon ; osteoporosis ; depression
asymptomatic pediatric Fontan ;PF
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
cell therapy ; chronic heart failure ;CHF
anemia ; HF
Lancet ; Anoop Shah ; air pollution ; heart failure ; morbidity ; mortality
ventricular assist devices ; cardiac nurses
america College of Physicians ; aCP
cardiac transplant ;ECCT ; transplant pool
MI-induced decreases ; septum (systolic) thickness ; LV posterior wall thickness ; LV internal diameter
reducd ; abnormal HR variability ; mortality
BAT n-terminal pro-brain natriuretic peptide
HF registry
economic Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model
obese older patients ; hFPEF ; caloric restriction ; aerobic exercise training
RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
SDQT-to-SDRR ratio ; HFVT
ventricular structure ; fiber/sheet orientation ; ca(2+) handling ; slowed conduction
Rad Q66p ; cardiomyopathy
sst2 titrated to high-dose BB ; cardiovascular event rate
serum resistin levels ; anthracycline-containing chemotherapy
acute RV failure ; pulmonary embolism
Exercise and Medical Therapies to Improve Cardiac Function ; pulmonar congestion
tachycardic response ; methylatropine ; vagal tone
mortality ; mortality ; cardiovascular mortality ;HF hospitalization
cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; kidney injury
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers
fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction
neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
Functional electrical stimulation ; peripheral muscles ; endothelial function ; heart failure patients ; preserved left ventricular ejection fraction
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure
Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm
postoperative survival ; patients ; preoperative hypoalbuminemia
nurse assessment ; cognitive impairment ; hospitalization
bisphosphonates ; alendronate ; etidronate ; risk of heart failure
Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INv group ; sham-INv ; sham levels ; renal DNx
patients ; advanced heart failure ;heart team ; cardiologists
elektrial activation ; dyssynchronous heart failure ;HF ; electromechanical behavior
HF-ACTION
hypertension ; diabetes mellitus ; systolic
tAPse vs pasp relationship ; nonsurvivors ; hFrEF ; HFpEF
in vivo inhibition ; mir-25 ; antagomir evoked spontaneous cardiac dysfunction ; murine myocardium to heart failure
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
haematopoietic cell transplantation ; hCT ; congestive heart failure ;CHF ; pre-HCT exposure to anthracyclines
NT-probNP levels
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases
carvedilol ; Î²-blocker metoprolol ; thromboembolic events ; heart failure
cardiac transplant survival
HF ; AMI ; pNA
dietary recommendations ; patients ; heart failure ;HF
arrhythmia substrate ; AMI ; HR variability
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin
hypertension ; compensated HFPEF ; DASh/sRD ; sodium
deranged Ca(2+) handling ; emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF
ejection fraction ; cardiac index ; inotropes
lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
ischemic ; ischemic heart failure samples ; healthy control
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; IRS2 ; insulin-signaling components regulating cellular metabolism
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing Outcomes Classification
8-fluo-cAMP binding ; wild type ; phosphomimic Ser77 ; Ser83 mutant RIÎ± proteins
preoperative albumin ; mortality
systolic heart failure ; QRs duration ; cRT
cox regression models ; propensity score decile ; oral glucocorticoid dosage ; HF hospitalisations ; loop diuretics
Functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; systolic function
dialysis patients ; HF hospitalization
reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; mortality ; readmissions in heart failure ; ejection fraction ;HFrEF ; heart rate
dyssynchronous HF ; electromechanical delay ;EMD ; myocyte depolarization ; myofiber shortening onset
QRs morphology ; duration ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial
biomarker studies ; biomarker-guided clinical trial
SAF cohort ; abnormal liver texture changes
transplant ineligible patients ; PD ; HF volume management
frailty ; weak grip strength ; physical exhaustion
cRT-D ; IE ; IC
low-volume EDs ; discharge patients ; heart failure home ; low-volume ED cases
acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; extra corporeal membrane oxygenation ;ECMO
right atrial myxoma ; massive embolism ; pulmonary arteries
undiagnosed heart disease ; HF
heart magnetic resonance imaging ; chelation choices ; patient compliance
ejection fraction ;EF ; pre-PD
cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133+ cells
Bax ; bcl-2 mRNA expression
nitroxyl ;hno ; Angeli's salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure
continuous-flow lVADs ; heartMate II ;HM II ; HeartWare ; bTT ; DT
EF ; blinded core laboratory
skeletal muscle mass assessed ; appendicular lean mass index
DASh diet scores ; HF
quality of life ; all-cause mortality
bNP ; inhospital mortality
cardiovascular diseases ; heart failure ;HF
heart failure ; left ventricular systolic dysfunction
CLCNKA polymorphism ; p.Arg83Gly ; heart failure ; glomerular filtration rate
ST2 ; functional capacity
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; b-treated ; drug-untreated failing hearts
figuur profiling ; cultured cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
exercise-induced PASp ; ventricular contractile reserve
Gene expression profile gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure samples
cardiac insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation
post-DASh/sRD brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Insights From Heart Failure ; HF-ACTION
derivation cohort ; coronary angiography ; systolic HF
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling
rhythm control ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
angiotensin II ;AngII ; hypoxia ; activators ; abnormal SCN5A mRNA splicing ; overexpress SCN5A variants
HF ; reduced ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene
hearts ; TTA/ttetMena mice ; wild-type littermates
hFrEF ; respiratory gas analysis
guideline-recommended drugs for heart failure ; chart review ; biomedical reasons
wasting ; fat ; lean mass ; HF
nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte
black race ; chronic HF ; modifiable risk factors ; lower exercise performance ; HF hospitalization
adverse event rates ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-Retn mice treated ; doxorubicin in vitro ; hRetn ;human resistin
lVADs ; CF devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; Framingham
FM ; plasma NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate response ; metoprolol
EH denotes ; HFpEF ; HF ; reduced EF ;HFrEF
plasma collected ; HF patients ; immunoreactive NT-probNP
beat-to-beat QT interval

power spectral analysis ; low-frequenncy/high-frequenncy ;LF/HF ratio ; CHF-INv ; sham-INv ; sham levels ; DNx
contractility ; ventricular-arterial coupling
hospital quality improvement initiative
n-terminal pro-b-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure
cardiac magnetic resonance postcontrast T1 time ; hFPEF
HF-ACTION ; left ventricular ejection fraction ; New York Heart Association class II to IV HF
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure
cardiac tissue ; TAC- ; sham-operated ; jQ1 ; vehicle ; BET inhibition suppresses a pathological cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models
systolic blood pressure ; left ventricular ;LV ; hypertrophy
conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction
admission NT-probNP
Peak oxygen consumption ;VO2max ; resting HR
follow-up
frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; incident HF
epigenetic readers in cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
CAD ; angiography ; systolic HF
Work load-corrected chronotropic response ; heart rate
gastrointestinal bleeding ; incessant ventricular tachycardia storm
Catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d consumed ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; clinical benefit
RV support ; lVAD ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail participants ; moderate ;HR ; ci
HF ; AMI
Chronic heart failure ;CHF ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
Î²-AR stimulation via catecholamine infusions ; rats enhanced PDE2 expression ; cAMP hydrolytic activity ; blunted cardiac Î²-AR responsiveness
chronic PAH ; hospitalized patients ; acute RV decompensation ; pharmacologic therapies
zSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; preserved left ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula
free-breathing pulse sequennce ; myocardial t1 ; swine model ; tachycardia-induced heart failure
PF cohort ;New York Heart Association classes I ; II ; III
comanagement ; patient preferences ; nonadherence
high-volume physicians ; low-volume physicians
Western Australian linked administrative health data
consensus report
diagnosis ; heart failure
nursing-sensitive outcome
miRNAs ; noncoding RNAs ; regulate expression ; target genes ; untranslated region ; messenger RNA
HFpEF ; ivabradine
Cardiac c-Kit+ cells ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
ps ; pulmonary embolism ; diabetes
pathophysiology ; HF
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pNA
mortality ; healthcare utilization ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction
heart failure ; preserved ejection fraction ;HFpEF
cox proportional hazards regression modeling ; risk factors ; i ; acute coronary syndromes ; coronary interventions
cyclic adenosine monophosphate ;cAMP ; augmented cyclic guanosine monophosphate ;c gMP
methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia ; CHF
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia
sphingosine-1-phosphate receptor ; s1PR1) ; Î²1-adrenergic receptor ;Î²1AR ; g-protein-coupled receptors
e-septal correlated ; PCWP ; e/e'lateral ; e/e'mean
inappropriate therapy ; atrial fibrillation ; carvedilol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone
Nordic walking ; standard cardiac rehabilitation ; functional capacity
cPG-recommended pharmacological treatment ; device consideration ; self-care education ; left ventricular function assessment
gLS ; LVEF ; sa in predicting adverse CV events
ERC induced recovery/enhancement ; DAPc protein levels ; sarcomeric microstructure ; markers ; Skm growth/differentiation ; myofibre regeneration
signalling cascades integrate ; microRNAs ; bHLh transcription factor Hand2 ; postnatal mammalian myocardium ; embryonic gene programs in heart failure
Rad Q66p limits ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms
EF ; LCx model ; LAD model ; stenting ; left ventricle
EH ; LV compliance ; CH ;LV end-diastolic volume ; idealized LV end-diastolic pressure ; Î² coefficient
mVA ; surgical ring implantation ; leaflet motion
hART enrolled patients ; New York Heart Association ;NYHA ; hospitalized ; HF
cardiac function ; echocardiography ; diastolic dysfunction
BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
English-language trials ; blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
Grading of Recommendations Assessment ; Development and Evaluation ;GRADe
HF
figuur ; right heart circulatory failure
ca(2+) influx ; voltage-gated ca(2+) channels ; ventricular action potentials ; excitation-contraction ;EC
ivabradine on exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction
aldosterone antagonism ; heart failure aldosterone ; neurohormone ; electrolytes
bNP ; glomerular filtration rate ; hypertension ; transmitral E-wave/early diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ;RAS axis ; natural vasodilatory ; diuretic peptides
Î²-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA
erythropoiesis-stimulating agent therapy
black race ; mortality/hospitalization ;hazard ratio ;HR
percutaneous one-vesel model ; chronic myocardial ischemia ; stent coated with a polytetrafluoroethylene tube
clinical ; genetic ; CHF predictive model
logistic analysis ; AT
heart failure ;HF ; tumor necrosis factor ;TNFÎ± ; tNF antagonists ; HF
Centers for Medicare and Medicaid Services ; cMS
cox proportional hazard models ; time-dependent covariates
severe CAD ; diameter stenosis ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes
hypertensive HFPEF ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
aldactone Evaluation Study ; symptomatic chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone
incidence and mortality outcomes ; heart failure ; acute myocardial infarction
CHF after HCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ;nonadherence
pathophysiological origin
lVAD surgery
creatinine ;hazard ratio
risk of death ; glomerular filtration rate
scientific literature ; HM II ; economische evaluations
dopamine ; low-dose nesiritide ; renal function
HR variability/turbulence
lVAD therapy ; transplantation eligibility status
bioc ; radial artery tonometry
magnetically levitated centrifugal-flow chronic lVAS
eRK1/2 signalling ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
breast cancer patients ; full Medicare coverage ; diagnosed ; stage I-III breast cancer ; chemotherapy
ejection fraction ; b-type natriuretic peptide levels ; patients hospitalized with heart failure ; inhospital outcomes
cardiomyocytes ; pde2 activity ; cGMP synthesis ; nitric oxide donors ; pde2 inhibition ; Î²-AR responsiveness
l-dko mice ; cardiac IRS1 ; IRS2 proteins ; heart failure ; cardiac energy metabolism ; p38Î± mitogen-activated protein kinase
ECs ; HDL ; phosphorylation ; eNOS-Ser(1177 ; eNOS-Thr ; PKc-Î²II-Ser
pasp ; peak o2 per kilogram
rCTs ; sts ; HH ; HM ; TM
mouse ventricular myocytes ; sarcomere shortening
administratie databases ; province of Alberta
heart failure ; myocardial collagen ; tissue
cRT ON assignment ; HF hospitalization ;hazard ratio
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR1) reciprocal downregulation ; cardiac hypertrophic response ; progression to heart failure
RR ; heart failure ; bisphophonates ; crude RR
hoog-cost Medicare fee-for-service beneficiaries ; Centers for Medicare and Medicaid Services demonstration ; clinics
physician adherence ; guideline recommendations in heart failure
nicorandil ; doxorubicin-induced heart failure ; rats
kccq summary scores ; New York Heart Association class ; HFpEF ; HF ; reduced EF
Rhythm control therapy ; af ; atrial structure ; function ; sinus rhythm
acute heart failure ; renal dysfunction ; low-dose dopamine ; nesiritide ; decongestion ; renal function
HF ; body composition ; skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography
heart failure treatment
aCP ; restrictive red blood cell transfusion strategy ; trigger hemoglobin threshold ; hemoglobin levels
infarction ; pneumonia
interatrial shunt
ventricular-pulmonary arterial coupling ;pulmonary vascular resistance
left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bTT ; transplant-ineligible patients ; destination therapy
Caloric Restriction ; aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Heart Failure ; Preserved ejection Fraction
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADIT-cRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac Resynchronization Therapy
oral glucocorticoids ; HF risk
HR ; ivabradine group
carvedilol ; inappropriate therapy
CHm ; adjunctive treatment
testosterone supplementation ; exercise rehabilitation
peak VO2 ; lean body mass
Guidelines-Heart Failure ; HF patients
economic Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness model ; disease management programs in heart failure
HFPSI ; risk of death ; all-cause medical hospitalization ; HF clinic outpatients
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model analysis ; pasp increase ; peak o2 per kilogram
pathophysiology ; heart failure ; preserved ejection fraction ; hFPEF ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVF ; cardioverter-defibrillator device
rGK ; rem2 ; rad ; Gem/Kir ; monomeric g proteins ; ventricular action potential duration ; EC coupling ; inhibit cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-MIBG
Swedish web-system for enhancement and Development ; evidence-based care in Heart disease Evaluated ; Recommended Therapies registry
LVEF ; clinical composite response ; reverse remodeling parameter
brain natriuretic peptide ; bNP
coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C
tAPse ;longitudinal RV fiber shortening ; PASp ;force generated ; in vivo RV length-force relationship
pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis mediating a negative cross talk
n-terminal probNP ;NT-probNP ; midregional proANp ;MR-proANp ; total adiponectin ; CHF
re-hospitalization
mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ; SS20 ; cardiac function ; proteomic remodeling
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction
hyperkalemia ; mineralocorticoid receptor antagonists ; heart failure
erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin products
uPR ; scn5a ; ventricular systolic HF tissue samples ; human induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; Î²-blockers
cochrane Effective Practice ; Organisation of Care Taxonomy
coPD ; CHF ; cRF
heart failure ; left ventricular ejection fraction ; aerobic training
implantable cardioverter-defibrillator deactivation ; clinical status
heart failure ; poor myocardial function
implantable cardioverter-defibrillator deactivation preferences
global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; adverse cardiovascular ;CV ; atrial fibrillation ;AF
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
MI characteristics yielded hazard ratios
national Medicare data ; HF ; AMI ; pNA
sst2 status ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model
HF ; HF ; HF ; preserved EF ; HF ; MI
EC ; HDL ;NYHA-IIIb ; phosphorylation ; eNOS-Ser(1177 ; phosphorylation ; eNOS-Thr
carvedilol ; Willebrand factor ; metoprolol
mouse heart failure ;HF model ; hypertensive heart disease ; HHD
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ca(2+)-pump ; phospholamban ; infarcted hearts
test-retest reliability ; Timed Up & Go ;TUG test ; advanced chronic obstructive pulmonary disease ;COPD ; chronic heart failure ;CHF ; chronic renal failure ;CRF
inmuscular testosterone supplementation ; chronic heart failure ;CHF
patients hospitalized ; HF ; LVEF ; long-term mortality
gLS outperformed left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa
heart failure ;HF ; plasma B-type natriuretic peptide ;bNP ; ejection fraction ;EF ; HF studies
RM ; home telemonitoring ;TM ; implanted monitoring devices ; medical support
cox regression analysis ; beta-blockers ; no beta-blockers ; inappropriate therapy
ethically complex situations ; pediatrics ; religious beliefs ; life-sustaining treatment
patient preferences ; competing priorities ; guideline-recommended medications
cost ; rhythm-control
median age ; women ; median left ventricular ejection fraction
fit ; unfit ; cRF distribution ; hazard ratios ; unfit men ; overweight body index strata
cRT group ; control group ; hazard ratio
HFPSI model ; blood urea nitrogen ; natriuretic peptide ; New York Heart Association class ; diabetes status ; atrial fibrillation/flutter
Medicare Patient Safety Monitoring System ;MPSMS database ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia
CD34+vegFR2+ cells ; functional capacity ; 10-cell decrease ; CD34+vegFR2+ cells
practice-level variation ; guideline-recommended treatment ; heart failure ; reduced ejection fraction
crude 28-day case-fatality rate ; concurrent HF
cohort ; sampling frame ; CHF
resting tension ; fpassive ;sarcomere length relations ; muscle strips ; kcl-KI treatment
reversibility ; heart failure ; myocardial infarction ;MI ; Î²-adrenoceptor blockade ; infarcted rats
aerobic ; resistance training ; augmented feedback ; exercise capacity ; muscle strength ; biomarkers
readmission ; acr ; Potential Preventable Readmission ; pPR ; Centers for Medicare and Medicaid ; cMS
congestive heart failure visits
exercise duration
arginine vasopressin ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; Î²-blockers
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation
sodium-restricted dietary approaches to stop hypertension diet ;DASh/sRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
rapid right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs
rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3
metoprolol ; carvedilol ; sympathetic activity
acute HF trials ; RELAX-aHF ; ASTRONAUT ; PRONTO
hospitalized HF ; international Classification of Diseases ; Ninth Revision ; Clinical Modification codes
Pulmonary capillary wedge pressure
Rad Q65p attenuates ; gating movement ; wild-type Rad
SS20 ; heart failure
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone
discharge
heart failure
heart failure discharges ; University of Connecticut health Center
wind association ;NYHA ; Class II Heart Failure ; eplerenone ; Placebo ; standard Heart Failure Medicines ;EMPHASIS-HF Study
echocardiograms ; left ventricular base ; midpapillary ; apex ; IVc occlusion ; biVP setting ; twist ; apical ; basal rotations ; RS
drugs ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin
HF induced in mice via phenylephrine ; haemodynamic stress ; surgical method of transverse aortic constriction ;TAC
muscle aerobic capacity ; postexercise phosphocreatine resynthesis
i-MIBG cardiac washout ; carvedilol ; metoprolol treatment ; Î²2-adrenergic receptor haplotype
advances in treatment ; acute myocardial infarction ;AMI
h-dko mice ; ventricular mass ; cardiac apoptosis ; fibrosis
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCX ; mid LAD
postmarketing trials ; risk ; hospitalized heart failure ;hHF ; dipeptidyl peptidase-4 ; dPP-4 ; antihyperglycemic agents
quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity index ;HFPSI ; University of Michigan HF clinic
pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; l-type ca2(+) current amplitude ; inotropic effect ; Î²-AR stimulation
inappropriate ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
cardiorespiratory fitness ;CRF ; body mass index ; heart failure ;HF mortality
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF study ; eplerenone in Mild Patients Hospitalization ; SurvIval Study in Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHF ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; vd ; interventricular delay ; vd ; STE analysis ; regional circumferential strain ;CS ; radial strain
New York Heart Association ;NYHA ; functional class III HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
non-LBBB ; QRs ; hazard ratio
abnormal Ca(2+) handling ; dyssynchronous HF ; myofiber shortening velocity ; septum ; depresses ; myofiber shortening ; stretch rate
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure
c-Kit+ cells ; transforming growth factor-Î² ; tGF-Î² ; epithelial to mesenchymal transition markers
pka subunits ; type II regulatory ;RIIÎ± ; catalytic ; cÎ± ; phosphorylation ; HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; Î²-blocker
g-protein-coupled receptors
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight ;SD ; diet group
RV dysfunction ;hazard ratio ; confidence interval ;CI ; cachexia
resting HR
tGF-Î² inhibition ; c-Kit+ cell phenotype ; function in vitro
NT-probNP ; inflammatory biomarkers ; hscrp ; IL6
BETs ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; functional status ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; burden of heart failure hospitalizations ; GDMT-treated NYHA functional class III HF
p70s6K ; PKc-Î²II ; HDL ;NYHA-IIIb ; malondialdehyde bound to HDL ;NYHA-IIIb
MLHF total score ; exercise ; diet
nonpace ; non-DNx ; sham-Innervated ; sham-INv ; nonpace DNx ; sham-DNx ; pace non-DNx ;CHf-INv ; pace DNx ;CHf-DNx
hABC Battery score ; HF risk ; health ABC HF model ;HR ; SD
frail ; biological phenotype ; risk of death
hemoglobin ; hgb ; HRQoL ; HRQoL ; patients in Heart Failure ; HF-ACTION
Atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; QuÃ©bec randomized to rhythm ; rate-control treatment strategies
heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism
calcineurin/Nfat signalling ; miR-25 expression integrate ; helix-loop-helix ;bHLh ; transcription factor dHAND ; diseased human ; mouse myocardium
PSSS ; btes
NT-probNP cutoff point ; pg/mL
prognostic power ; r-R interval oscillations ; non-linear HR variability ; short-term fractal scaling exponent
diastolic function ; diastolic filling formalism ; relaxation/viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; spontaneous ventricular tachycardia ;HFVT ; HF patients ; spontaneous VT ;HFVT
gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF
VAD group ; ventricular assist device support ; ECMO ; extracorporeal membrane oxygenation membrane support
risk factors ; ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-D
cost-effectiveness ; heart failure disease management programs
humanized mouse model lacking murine resistin ; transgenic for the human Retn gene ; hum-Retn mice ; inflammation-stimulated resistin levels
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; Î²-blockers
TTA/ttetMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction
resynchronization-Defibrillation for Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT
heart failure patients ; Italy ; confirmatory factor analysis ; cFA ; SCHFI ;Self-Care Maintenance ; Self-Care Management ; Self-Care Confidence
functional status ; wt ; NYHA class ; HFpEF ; hFrEF ; adherence to prescribed therapy ; HFpEF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-ERk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling
CHF ; SD testosterone levels ; nmol/L
functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; degenerative mitral valve
New York Heart association class ; kccq overall Summary ; Total Symptom domains ; Spearman correlations ; 2-way aNOVA ; patients ; HF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; Î²-blockers
c57BL/6 male mice ; ANG II infusion ; uninephrectomy ; ANG II infusion ; salt loading
early transmitral blood flow velocity over tissue ; doppler early diastolic mitral annulus velocity ; e/e ; pulmonary capillary wedge pressure ; pcWP ; decompensated systolic heart failure ;HF
LV systolic indices ;LV ejection fraction ; LV strain ;strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow
peak VO2
age- and sex-adjusted risk ; HF
AMI patient ; hospital ; best quintile of performance ; hospital Compare
Mass spectrometry ; n- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis ; leu3-Gly4 ; pro6-Gly7
ctnt ; NT-probNP ; HF prediction model
HFpEF patients ; HFpEF patients ; New York Heart Association class II ; III
depressed left ventricular ;LV ; systolic pressure ; pressure development ; ejection fraction ; fractional shortening ; cardiac output
baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction
enrollment period
HF risk factors ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ; rheumatic fever ; Chagas' disease
adjusted hazard ratios ; moderate ; low cRF categories
kccq category ; HFpEF
eGFR group II ; eGFR group III ; eGFR group IV ; uncontrolled hypertension ; diuretics
myocardial phosphodiesterase-2 ; pde2) ; heart failure ;HF ; pde2-mediated effects on beta-adrenergic receptor ;Î²-AR ; cardiomyocytes
cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; inappropriate ATP ; shock therapy ; metoprolol
epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-Sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
risk of death ; urgent readmission
mena overexpression ; TTA/tgtetMena mice ; TAC surgery
echocardiography ; LV end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; pressure gradient
PD ; diuretic refractory severe-end-stage HF
ATP ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium
New York Heart Association class III heart failure ;HF ; left ventricular ejection fraction ; p
bottleneck stent ; proximal LAD ; LCX ; reversible myocardial ischemia ;open stent ; ischemic heart failure
potassium ; spironolactone ; non-AAs
obese participants ; mean ;SD ; body mass index ; chronic ; stable HFPEF
proangiogenic effects ; B act via activation of VEGF pathway ; rats ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; control adenovirus ; ad-c
post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement
exercise-induced pulmonary artery systolic pressure ;PASp ; stress Doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
literature search ; MEDLINE ; EMBASE ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institut ; Centre for Reviews and Dissemination ; evidence Based Practice Centres
veterans ; systolic heart failure ; Î²-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS synchrony ; CS
tAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe/PASp ; cox regression ; kaplan-meier analyses
symptom limited maximal cPET ; CHF
human heart failure ;HF ; mRNA splicing ; voltage-gated cardiac na+ channel Î±-subunit ; scn5a ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease treatment strategies
economic Analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness model
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-B-type NP ; acute heart failure ; Emergency Department (ED ; acute dyspnea
peak oxygen consumption ;peak VO2) ; ven/ vCO2 slope ; exercise oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETCO2)
europese retrospective cohort study ; Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS
tolvaptan ; severe hyponatremia ; Japan ; congestive heart failure patients ; optimal diuretic therapy
global longitudinal strain ; left ventricle ; echocardiographic measurements
platelet-activating factor ;PAF ; metabolic enzymes
acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; intravenous inotropes ; ventricular assist devices ;VADs
HFpEF ; ivabradine ; exercise capacity ; left ventricular filling pressure response to exercise ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAAS ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade
lVET ; unfavorable outcome
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; Î²-blockers
cardiac performance ; Î²-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling
adjusted median rate ratio
congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; mitochondrial proteome changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; Î±-myosin heavy chain
HDL ; CHF-NYHA-III ;HDL ;NYHA-IIIb
coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
mDC ; mDC95%
baseline ; heart failure T1-mapping values ; contrast agent
HF ; dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol related
ST2 levels ; functional capacity ; long-term clinical outcomes ; ambulatory patients ; HF enrolled in the Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACTION
cardiopulmonary exercise testing ; exercise rehabilitation ; chronic heart failure ;CHF
ischemic HF pathogenesis ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-ACTION ; exercise training ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire
cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; systolic left v entricular dysfunction ;REVERSe ; left ventricular ;LVEF
glomerular filtration rate ; eGFR ; eGFR ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLCNKA GG genotype
echocardiography ; LV end-diastolic dimension ; LV end-diastolic pressure ;wall stress ; lung weight
e-lateral ; aUC
spironolactone ; risk of hospitalization
rate-control patients ; cardiac procedures ; p ; cardioversions ; kosten ; antiarrhythmic drugs
descriptive assessment ; diabetes mellitus ; cardiomyopathy origin ; Î²-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone post myocardial infarction Heart failure Efficacy ; SUrvival Study ;EPHESUS ; post-myocardial infarction patients ; heart failure ; hospitalizations ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; inappropriate implantable cardioverter-defibrillator therapy ; MADit-cRT ;Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy
risk reduction ;HR ; 95% confidence interval
DASh/sRD reduced clinic ; 24-hour brachial systolic pressure
HF ; obese ; body mass index ; kwh ; black ethnicity ; idiopathic-dilated cardiomyopathy
mortality ; HF ; LVEF
idiopathic dilated cardiomyopathy ; negative coronary angiography
europese society of cardiology guidelines ; hFPEF ; heart failure ; preserved LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; inimpaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
Î²1ARs ; s1PR1s ; myocyte ; cAMP production
PAF-cPT ; PAF levels ; lyso-PAF-AT ; p
heart failure ;mean ejection fraction
dRS-stratified hazard ratios ; ci ; sitagliptin ; pioglitazone ; ci
skeletal muscle mass ; t-score
testosterone group ; peak oxygen uptake ; Beck depression Inventory ; leg strength ; Medical Outcomes ; Short-Form quality of life domains
RAS- ; Î²-blocker uptitrations ;
Heart Failure ; controlled trial Investigating Outcomes of Exercise Training ;HF-ACTION ; social support ; barriers to exercise score
ST2 ; cardiovascular death ; HF hospitalization ;hazard ratio ; log2 ng/mL
New York Heart Association Class I/II Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; low-dose nesiritide ; pg/kg/min ; bolus
cRT ; New York Heart Association class III ; IV heart failure ; left ventricular ejection ; QRs duration ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; stable HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes
HF ; lyso-PAF-AT ; PAF-cPT ; PAF levels ; PAF-AH ; lp-PLA2
medical therapy ; redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure
plasma N-terminal pro-b-type natriuretic peptide ;NT-probNP
cardiac troponin T ;ctnT ; biomarkers ; incident HF ; HF risk prediction ; Atherosclerosis Risk in Communities ;ARIc
body mass index ;HR per kg/m(2)
nc=235 ; men ; median age ;interquartile range ; median body mass index
reverse remodeling ; ejection fraction ; mortality ; HF hospitalizations
EH ; reducd LV contractility ; CH ; lower LVEF ; Î² coefficient ; ci ; systolic blood pressure
echocardiography ; dilated LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; mild MR ; mitral valve opening ; MS ; mVA ; pressure gradient
multicenter ; double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction
BETs ; chromatin-mediated signal transduction to Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor ; activated T cells ; nFAT ; nuclear factor-Îºb ;NF-Îºb
mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death
all-cause ; cardiovascular mortality
EO-cFUs ; diabetes ; 10-EO-cFU increase ; peak VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type Ca2 ; cardiomyocytes ; experimental HF
east ; Atrial fibrillation ; Stroke prevention Trial
OUTCOMes ; Exercise capacity ; peak oxygen consumption ;VO2 ; ml/kg/min ; QOL ; Minnesota Living with Heart Failure ;MLHF
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function
patients ; low left ventricular ejection fraction ; patients ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians busy ; acute and outpatient settings
HF patients ;HFrEF ; preserved left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; n-terminal pro-brain-type natriuretic peptide assessment
low-volume EDs
cardiac transplant ; ECCT patients ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
HABC Battery scores ; Health ABC HF Risk model ; discrimination ; c-index ; nc ; ci
cfi ; RMsea ; Self-Care Maintenance Scale ; cFI ; RMsea ; Self-Care management Scale ; cFI ; RMsea ; self-Care Confidence scale
BAT ; quality-of-life score ; NYHA functional class ranking
preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; lVAD
commissie ; acute myocardial infarction ;AMI
management ; heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation
SAF ; PF mean ; central venous pressure ; g ; sVR index
admission median BNP levels ; reduced EF ; preserved ; pg/mL
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
LV ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; allopurinol rats ; maximum o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ; vh ; relative wall thickness ;RWt ; CR ; vh ; rWT ; CH ; vh ; rWT
angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring 30
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory
interaction term analysis ; severely reduced LVEF ; risk ; long-term mortality
wstar-kyoto ; lean zSF1 ; obese zSF1 ; obese zSF1 ; high-fat diet ; euthanization
kaplan-meier curves ; log-rank testing ; risk stratification ; eu/VA/VA-RT cohorts
multivariate cox regression analyses ; AF type ; lack of hypertension
chronic HF-REF ; NYHA functional class II ; eGFR ; potassium ; eplerenone
fFM ; fFM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; CC ;non-cachectic CHF ; myocardial infarction-both
spironolactone ; HF ;hazard ratio ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump function ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF hospitalization
index ED visit ; low-volume ED cases
implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ;hazard ratio ; 95% confidence interval ; pulmonary vascular resistance
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association class I to III ; echocardiographic ; cardiopulmonary exercise test
abd classification ; American college of cardiology ; acc ;American Heart Association ; AHA ; New York Heart Association ;NYHA
mVA ; v end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; mVA ; velocity time integral ; mitral filling flow ; continuous wave doppler echocardiography ; MR
statitistical significance ; RM trended to reduce all-cause mortality ; sts HH
HFPSI ; Ann arbor Veterans Affairs HF clinic ;VA cohort ; HFPSI ; va-RT cohort
spironolactone dose ; hyperkalemia ;potassium
preserved LVEF ; risk of long-term mortality
HFpEF ; egs ratio ; NYHA class III ; p = 0.008)
pulmonary arterial systolic pressure ;PASp ; right ventricular ;rv ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole
severe CAD ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension
receiver operating characteristic curve ;AUc ; e/e ; pcWP estimation ; e/elateral
trastuzumab-treated patients ; coronary artery disease ;HR
LVEF ; clinical composite response ; cRT ON ; cRT OFF
tGF-Î² signaling ; inhibiting TGF-Î² receptor type I ; smad 2/3 ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial to mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
HFrEF ; diuretics ; co-morbidities ; NYHA class III
HF disappeared ; postoperative echocardiography ; LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; MR ; mitral valve opening ; mVA
systolic heart failure ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; If inhibitor ivabradine trial ; ivabradine ; ivabradine
tAPse/PASp ;hazard ratio ; tAPse ; p ; 0.01 ; New York Heart Association functional class
Chronic Kidney Disease Epidemiology Collaboration equation ; glomerular filtration rate ; eGFR
paraDIGm-HF ; stabilized chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYHA II-III ; bNP ; bNP ; cardiovascular death ; hospitalization for heart failure
LV reverse remodeling ; pre-cRT LV ; dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular
hyperkalemia ; African Americans ; non-AAs ; white ; New York Heart Association ;NYHA ; IV HF ; left ventricular dysfunction ; spironolactone
iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dko
natriuretic peptide ; n-terminal pro-B-type natriuretic peptide ; monotype natriuretic peptide ; bNP ; n-terminal fragment ;nt-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers
ivabradine ; ivabradine
liberal transfusion protocols ; aggressive protocols
risk of death ; unplanned readmission
hek ;human embryonic kidney ; Î²1AR ; s1PR1 downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; Î²-adrenergic receptor agonist
kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression Inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke
diastolic function ; c=24.3 ; p=0.03 ; ea
disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; ci ; saxagliptin ; pioglitazone ; ci
revascularization ;coronary artery bypass surgery ; hazard ratio ;HR ; percutaneous coronary intervention ; HR ; systolic blood pressure
biomedical treatment ; biomedical treatment ; CHm ; left ventricular ejection fraction ; ci ; left ventricular diastolic end diameter
open-label crossover study ; stable heart failure patients ; left ventricular ejection fraction ; arg16/ gln27 ; gly16/ glu27 haplotype ; Î²2-receptor
low-volume ED cases
risk-adjusted all-cause mortality ;hazard ratio ; 95% confidence interval ; ci
multivariable-adjusted hazard ratios
ctnt ; NT-probNP ; aRIC HF model ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate
eplerenone ; hyperkalemia ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; NYHA ; glomerular filtration rate ; eGFR
low-dose nesiritide ; cumulative urine volume ;nesiritide
standard care ; Nordic walking ; functional capacity
hyperkalemia ; wRF ; diabetes ; eGFR ; systolic blood pressure ; hg
PAF ; biosynthetic enzymes ;lyso-PAf acetyltransferase ;lyso-PAf-AT ; dithiothreitol ; dTT ; CDp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ;PAf-acetylhydrolase ;PAf-AH ; lipoprotein-associated phospholipase A2 ; lp-PLA2]
ivabradine group ; follow-up exercise capacity
CHF ; ods Ratio ; ods Ratio ; p ; hypertension ; RAC2 ; doxorubicin efflux transporter ABCc2
NYHA classification ; class III ; class III ; class I
low-dose dopamine ; cumulative urine volume ;dopamine ; 229 mL ; p ; cystatin C level
haard ratio ;HR ; confidence interval ; ci ; baseline glomerular filtration rate ;HR ; 15-mL/min ; chronic obstructive pulmonary disease ; diabetes ; lager ; peripheral vascular disease
peak oxygen uptake ; p<0.001 ; hazard ratio ; confidence interval ; ci=0.97-0.98) ; ventilatory efficiency slope ; HR=1.02 ; hemoglobin ; HR=0.931 ; left ventricular ejection fraction
Kansas City Cardiomyopathy Questionnaire summary ; p = .006 ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter
